Telomir Pharmaceuticals, Inc

PRESS RELEASE

published on 10/09/2025 at 13:30, 7 months 12 days ago

Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells
Telomir Pharmaceuticals announces new findings showing Telomir-1's impact on aggressive breast cancer cells, targeting iron-dependent regulation and cellular energy pathways

Telomir-1 Telomir Pharmaceuticals Breast Cancer Cells Iron-dependent Regulation Cellular Energy Pathways
BRIEF

published on 10/07/2025 at 13:35, 7 months 14 days ago

Telomir Pharmaceuticals dévoile des résultats précliniques prometteurs dans le traitement du cancer de la prostate

Cancer De La Prostate Telomir-1 Telomir Pharmaceuticals Thérapie Épigénétique Suppresseurs De Tumeurs
BRIEF

published on 10/07/2025 at 13:35, 7 months 14 days ago

Telomir Pharmaceuticals Unveils Promising Preclinical Results in Prostate Cancer Therapy

Prostate Cancer Telomir-1 Telomir Pharmaceuticals Epigenetic Therapy Tumor Suppressors
PRESS RELEASE

published on 10/07/2025 at 13:30, 7 months 14 days ago

Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance
Telomir Pharmaceuticals unveils new preclinical findings showing Telomir-1 reactivates tumor suppressor genes MASPIN and RASSF1A in aggressive prostate cancer models, offering potential for improved chemotherapy response and metastasis control

Prostate Cancer Telomir-1 Telomir Pharmaceuticals Preclinical Findings Tumor Suppressor Genes
BRIEF

published on 09/18/2025 at 14:05, 8 months 3 days ago

Telomir-1 Shows Expanded Targeting of Histone Demethylases

Telomir-1 Telomir Pharmaceuticals Epigenetic Therapy Histone Demethylases Cancer And Aging
BRIEF

published on 09/18/2025 at 14:05, 8 months 3 days ago

Telomir-1 montre un ciblage élargi des déméthylases d'histones

Telomir-1 Telomir Pharmaceuticals Thérapie Épigénétique Histone Demethylases Cancer Et Vieillissement
PRESS RELEASE

published on 09/18/2025 at 14:00, 8 months 3 days ago

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies
Telomir Pharmaceuticals announces Telomir-1's new in vitro results inhibiting KDM5 family, expanding epigenetic therapy possibilities in cancer treatment and aging slowdown

Telomir-1 Telomir Pharmaceuticals Epigenetic Therapy KDM5 Family Inhibition Cancer Aging Treatment
BRIEF

published on 09/09/2025 at 14:05, 8 months 12 days ago

Telomir Pharmaceuticals Unveils Promising Preclinical Cancer Data

Cancer Research Telomir-1 Telomir Pharmaceuticals DNA Methylation CDKN2A
BRIEF

published on 09/09/2025 at 14:05, 8 months 12 days ago

Telomir Pharmaceuticals dévoile des données précliniques prometteuses sur le cancer

Telomir-1 Telomir Pharmaceuticals Recherche Sur Le Cancer Méthylation De L'ADN CDKN2A
PRESS RELEASE

published on 09/09/2025 at 14:00, 8 months 12 days ago

Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy
Telomir Pharmaceuticals announces new preclinical findings showing Telomir-1's ability to reverse CDKN2A gene silencing by DNA methylation, potentially restoring cancer cell cycle control and immune surveillance

Cancer Therapy Telomir Pharmaceuticals Preclinical Findings DNA Methylation CDKN2A Gene

Published on 05/21/2026 at 23:00, 32 minutes ago

Silver Wolf Adopts Semi-Annual Financial Reporting
Published on 05/21/2026 at 23:00, 32 minutes ago

Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call
Published on 05/21/2026 at 23:00, 32 minutes ago

Revival Gold Announces Adoption of Shareholder Rights Plan and Corporate Update
Published on 05/21/2026 at 22:15, 1 hour 17 minutes ago

Linear Announces Acquisition, Share Consolidation and Private Placement
Published on 05/21/2026 at 15:00, 8 hours 32 minutes ago

Karbon-X Expands Global Energy Attribute Certificate Market Capabilities Amid Growing Renewable Procurement Demand

View all ACCESSWIRE

Published on 05/21/2026 at 21:45, 1 hour 47 minutes ago

Rendeavour becomes the African Continental Free Trade Area's inaugural implementation partner for African industrialisation and trade infrastructure
Published on 05/21/2026 at 20:10, 3 hours 21 minutes ago

Ernst Russ AG Divests MV 'EF Emira' and Raises Full-Year 2026 Guidance
Published on 05/21/2026 at 20:05, 3 hours 26 minutes ago

EQS-Adhoc: Ernst Russ AG: Upward revision of the guidance for the financial year 2026
Published on 05/21/2026 at 20:00, 3 hours 32 minutes ago

VINFAST INTRODUCES THE NEW-GENERATION VF 8, FEATURING COMPREHENSIVE ENHANCEMENTS
Published on 05/21/2026 at 18:26, 5 hours 5 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares

View all EQS

Published on 05/21/2026 at 17:50, 5 hours 42 minutes ago

CDA - H1 results 2025 2026
Published on 05/21/2026 at 17:45, 5 hours 47 minutes ago

CEGEDIM: DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 05/21/2026 at 17:45, 5 hours 47 minutes ago

CEGEDIM: DECLARATION D’ACTIONS ET DE DROITS DE VOTE
Published on 05/21/2026 at 17:45, 5 hours 47 minutes ago

CDA - Résultats de 1er semestre 2025 2026
Published on 05/21/2026 at 16:35, 6 hours 56 minutes ago

260521 BENETEAU Déclaration du nombre d'actions et de droits de vote au 30-04-2026

View all LES ECHOS COMFI WIRE

News